Intensive Care Unit, Instituto Nacional de Câncer, Praça Cruz Vermelha, 23, 10 andar – Centro, Rio de Janeiro-RJ, Brazil 20230-130
Immunopharmacology Laboratory, Instituto Oswaldo Cruz, FIOCRUZ, Av. Brasil, 4365, Rio de Janeiro-RJ, Brazil 21045-900
Medical Intensive Care Unit, Hospital de São Francisco Xavier. Centro Hospitalar de Lisboa Ocidental, Estrada do Forte do Alto do Duque, CEP 1449-005 Lisboa, Portugal
Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Av. Brasil, 4365, Rio de Janeiro-RJ, Brazil 21045-900
Following the publication of the above article
Recent literature on the role of corticosteroids in severe community-acquired pneumonia
Reference
Study design
Sample size, number
Patient selection
Corticosteroids (drug/regimen)
Primary endpoints
Level of evidence and recommendation
Marik,
Single-center RCT
30
Severe CAP
Hydrocortisone 10 mg/kg versus placebo 30 minutes before antibiotics
Mortality, clinical course, and serum TNF-α levels
Weak recommendation, moderate-quality evidence
Confalonieri,
Multicenter RCT
46
Severe CAP
Hydrocortisone 200 mg + hydrocortisone 10 mg/hour, for 7 days versus placebo
Mortality, clinical course, and Systemic inflammation
Strong recommendation, moderate-quality evidence
Mikami,
Open label RCT
31
Moderate and severe CAP
Prednisolone 40 mg qd, for 3 days versus placebo
Mortality and clinical course
Weak recommendation, low-quality evidence
Garcia-Vidal,
Retrospective cohort study
308
Severe CAP
Methylprednisolone 45 mg (or equivalent) qd for 11.4 days
Mortality
Strong recommendation, low-quality evidence
CAP, community-acquired pneumonia; qd,
Competing interests
The authors declare that they have no competing interests.